When added to human serum and reacted with lymphoma cells opsonized with the type I anti-CD20 mAbs rituximab and ofatumumab, the recombinant triple C2 mutant formed convertases of higher activity and extended stability compared to those built from the wild-type C2 protein [8]. This evidence concerns the gene C2 and lymphoma.